Apostolia M. Tsimberidou

Jul 30, 2024 | nature.com | Sarina Piha-Paul |Vivek Subbiah |Aung Naing |Jaffer Ajani |Kanwal Raghav |Gordon Mills | +3 more

AbstractCancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto one of four cohorts based on molecular alterations: (1) somatic BRCA1/2, (2) other homologous recombination repair pathway, (3) PTEN and (4) germline BRCA1/2.

Apr 18, 2023 | nature.com | Omar Alhalabi |Roman Groisberg |Andrew Hahn |Aung Naing |Apostolia M. Tsimberidou |Timothy A. Yap | +2 more

AbstractPre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. NCT03430882 enrolled patients with mTOR pathway aberrant tumors to receive sapanisertib, carboplatin and paclitaxel. Primary objective was safety and secondary objectives were clinical response and survival. One patient had a dose-limiting toxicity at dose level 4. There were no unanticipated toxicities.